Drug Trial Radar · NCT06116916
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
185
Actual
Start
Jan 9, 2024
Primary completion
Oct 31, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Kyowa Kirin Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.
Conditions
- Diabetic Macular Edema (DME)
Interventions
KHK4951Drug
KHK4951 eye drop for 36 weeks until end of the trial
Aflibercept InjectionDrug
Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baselineTime frame: For 36 weeks until the end of the trial
Locations
87 sites in 4 countries. Site status is shown where the registry gives one.
Barnet Dulaney Perkins Eye Center - Phoenix
Mesa, Arizona
Retina Associates Southwest, P.C.
Tucson, Arizona
Win Retina
Arcadia, California
Retina Vitreous Associates Medical Group
Beverly Hills, California
The Retina Partners
Encino, California
Salehi Retina Institute, Inc
Huntington Beach, California
California Eye Specialists Medical Group Inc
Pasadena, California
Retina Consultants of Southern California
Redlands, California
Retina Consultants of Southern CO
Colorado Springs, Colorado
Blue Ocean Clinical Research West
Clearwater, Florida
Florida Eye Associates
Melbourne, Florida
Eye Associates of Pinellas
Pinellas Park, Florida
Ft. Lauderdale Eye Institute
Plantation, Florida
Retina Vitreous Associates of Florida - Saint Petersburg
St. Petersburg, Florida
Southern Vitreoretinal Associates
Tallahassee, Florida
Center for Retina and Macular Disease - Ophthalmology
Winter Haven, Florida
Mid Atlantic Retina Specialists - Hagerstown
Hagerstown, Maryland
Sierra Eye Associates
Reno, Nevada
Envision Ocular, LLC
Bloomfield, New Jersey
Vision Research Center Eye Associates of New Mexico
Albuquerque, New Mexico
Retina Vitreous Surgeons of Central NY, PC
Liverpool, New York
Ophthalmic Consultants of Long Island
Oceanside, New York
Retina Vitreous Center in Edmond Oklahoma
Edmond, Oklahoma
EyeHealth Northwest
Portland, Oregon
Wills Eye Health System
Bethlehem, Pennsylvania
Eye Care Specialists
Kingston, Pennsylvania
Retina Consultants of Charleston - (RCA Network Site)
Charleston, South Carolina
Charleston Neuroscience Institute (RCA Network Site)
Ladson, South Carolina
Black Hills Regional Eye Institute - Ophthalmology
Rapid City, South Dakota
Charles Retina Institute
Germantown, Tennessee
Retina Research Institute of Texas
Abilene, Texas
Austin Retina Associates - Ophthalmology/Retina (RCA Network site)
Austin, Texas
Austin Clinical Research, LLC
Austin, Texas
Retina Consultants of Texas
Bellaire, Texas
Texas Retina Associates
Fort Worth, Texas
Retinal Consultants of Texas- San Antonio (RCA Network site)
San Antonio, Texas
Retina Consultants of Texas (RCA Network Site)
The Woodlands, Texas
Strategic Clinical Research Group, LLC
Willow Park, Texas
University of Vermont Fletcher Allen Health Care
Burlington, Vermont
Retina Group of Washington
Fairfax, Virginia
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.